Clozapine treatment during the adolescent period reverses behavioral deficits in a dual-hit mouse model combining prenatal stress and maternal immune activation
Pharmacology Biochemistry and Behavior · 2026
DOI: 10.1016/j.pbb.2026.174179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2026. Verfasst von Hak-Jae Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea; Advanced Pharmacology and Physiology …. Hauptthemen laut MEDLINE: Clozapine, Prenatal Exposure Delayed Effects, Stress, Psychological, Behavior, Animal. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Prenatal stress (PNS) and maternal immune activation (MIA) are known risk factors for psychiatric disorders. However, the effects of combining these two factors remain unclear. We investigated the behavioral consequences of dual exposure to PNS and MIA in mice and evaluated whether clozapine treatment during the adolescent period could reverse these changes. METHODS: We established a dual-factor mouse model by administering poly(I:C) (5 mg/kg) on gestational day 9 and applying repeated variable stress from gestational days 14 to 21. Male offspring were tested for prepulse inhibition (PPI), social interaction, and open-field activity. Clozapine (2 mg/kg/day) was administered from postnatal days 35 to 56. Prefrontal cortex protein changes were screened using 2D electrophoresis and MALDI-TOF mass spectrometry. RESULTS: PNS + MIA offspring showed significant deficits in multiple behavioral areas, including a 77% reduction in central zone entries (4.71 ± 2.81 vs. 20.28 ± 6.39 in controls), increased immobility, impaired social interaction, and reduced sensorimotor gating. Clozapine treatment during the adolescent period normalized these behavioral abnormalities without affecting control animals. Proteomic analysis identified several altered proteins, including decreased Sptan1 and increased Glul levels, suggesting changes in the cytoskeleton and glutamate metabolism. CONCLUSION: Combined PNS and MIA exposure produces clear behavioral deficits related to schizophrenia that are effectively reversed by clozapine treatment during the adolescent period. These results support the validity of this dual-hit model and suggest that early pharmacological intervention can be effective during critical developmental periods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea; Advanced Pharmacology and Physiology Integrated Sciences (AXIS), College of Medicine, Soonchunhyang Univers…
- Advanced Pharmacology and Physiology Integrated Sciences (AXIS), College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea; Department of Physiology, College of Medicine, Soonchunhyang University, Cheona…
Zitieren
APA
Kim, H. J., Kang, S., Kwon, J. T., Kim, J., Jung, Y. H., Cha, M., & Lee, J. B. (2026). Clozapine treatment during the adolescent period reverses behavioral deficits in a dual-hit mouse model combining prenatal stress and maternal immune activation. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2026.174179
Vancouver
Kim HJ, Kang S, Kwon JT, Kim J, Jung YH, Cha M, et al. Clozapine treatment during the adolescent period reverses behavioral deficits in a dual-hit mouse model combining prenatal stress and maternal immune activation. Pharmacology Biochemistry and Behavior. 2026. doi:10.1016/j.pbb.2026.174179
BibTeX
@article{Kim2026,
author = {Kim, Hak-Jae and Kang, Shinwoo and Kwon, Jun-Tack and Kim, Jin and Jung, Young Hyun and Cha, Myeounghoon and Lee, Jeong Beom},
title = {Clozapine treatment during the adolescent period reverses behavioral deficits in a dual-hit mouse model combining prenatal stress and maternal immune activation},
journal = {Pharmacology Biochemistry and Behavior},
year = {2026},
doi = {10.1016/j.pbb.2026.174179}
}
EUVIMED